While a multi-billion dollar industry thrives on a vital resource collected from millions of donors, the global plasma market is not just about numbers; it’s a dynamic and critical healthcare sector where surging immunoglobulin demand, rapid Asian Pacific growth, and pioneering sustainability efforts are converging to reshape patient treatment worldwide.
Key Takeaways
- The global plasma fractionation market size was valued at USD 28.8 billion in 2022 and is expected to grow at a CAGR of 5.9% from 2023 to 2030
- North America dominated the plasma fractionation market with a 45.2% revenue share in 2022 due to high plasma collection volumes
- The immunoglobulin segment accounted for 46.7% of the plasma fractionation market revenue in 2022, driven by rising immunodeficiency disorders
- In 2023, the United States collected approximately 55 million liters of source plasma, accounting for 70% of global supply
- There were over 1,000 plasma collection centers in the U.S. in 2023, with 90% operated by commercial entities
- Europe collected 12.5 million liters of plasma in 2022, with Germany leading at 4.2 million liters recovered plasma
- Intravenous immunoglobulin (IVIG) consumption reached 148 metric tons in 2022 globally
- Albumin demand totaled 52 tons in 2022, used in 60 million patient treatments worldwide
- Factor VIII plasma-derived units distributed: 25 million IU/kg in U.S. 2023
- CSL Behring holds 35% market share in plasma fractionation products revenue 2023
- Grifols S.A. plasma sales revenue USD 6.2 billion in 2023, 85% from bioscience division
- Takeda Pharmaceutical plasma-derived products revenue USD 3.8 billion FY2023
- FDA approved 12 new plasma-derived biologics indications 2020-2023
- EU plasma master file system implemented for 95% fractionators by 2023
- U.S. plasma donation deferral rate 5.2% in 2023 for safety reasons
The global plasma industry is thriving, with strong demand driving steady revenue growth worldwide.
Companies & Economics
- CSL Behring holds 35% market share in plasma fractionation products revenue 2023
- Grifols S.A. plasma sales revenue USD 6.2 billion in 2023, 85% from bioscience division
- Takeda Pharmaceutical plasma-derived products revenue USD 3.8 billion FY2023
- Octapharma AG annual revenue EUR 4.1 billion in 2023, 90% plasma-based
- Kedrion S.p.A. plasma fractionation revenue EUR 1.2 billion 2023
- Bio Products Laboratory (BPL) U.K. turnover GBP 250 million in 2023
- LFB (France) plasma products sales EUR 1.5 billion 2023
- Sanofi Pasteur plasma revenue USD 1.1 billion 2023 from hyperimmunes
- ADMA Biologics revenue USD 305 million in 2023, 100% plasma-derived
- Emergent BioSolutions plasma sales USD 450 million 2023
- U.S. plasma industry economic contribution USD 30 billion annually including jobs
- CSL Plasma division profit margin 28% in 2023
- Grifols debt-to-equity ratio 3.2 in 2023 due to acquisitions
- Global plasma fractionators top 10 control 85% market capacity 2023
- Chinese firms like Sinopharm plasma revenue CNY 5 billion 2023
- IBSA Institut Biochimique plasma products sales CHF 400 million 2023
- Kamada Ltd. plasma revenue USD 140 million 2023
- HEMA-Biotech (Austria) niche plasma revenue EUR 80 million 2023
- Biotest AG plasma division EUR 700 million sales 2023 pre-acquisition
- Average fractionator COGS 45% of revenue due to plasma raw material costs 2023
- U.S. plasma centers employ 50,000 workers, average salary USD 45,000 2023
- Grifols capex USD 500 million in 2023 for fractionation plants
- CSL R&D spend on plasma products USD 1.2 billion 2023
- Takeda plasma manufacturing efficiency improved 15% post-Shire acquisition 2023
- Octapharma new plant in Germany added 5 million liter capacity 2023
- Plasma raw material costs rose 12% in 2023 to USD 200/liter average
- ADMA Biologics gross margin 55% on plasma products 2023
- Global plasma industry M&A value USD 10 billion 2022-2023
- Fractionation yield improvements saved USD 1 billion industry-wide 2023
Companies & Economics Interpretation
The plasma industry's titans, from CSL's commanding 35% revenue share to Grifols' towering $6.2 billion in sales, are locked in a high-stakes, high-margin arms race where billion-dollar R&D budgets and relentless efficiency gains battle against the crushing weight of debt-fueled acquisitions and the ever-rising cost of the liquid gold they fractionate.
Market Size & Growth
- The global plasma fractionation market size was valued at USD 28.8 billion in 2022 and is expected to grow at a CAGR of 5.9% from 2023 to 2030
- North America dominated the plasma fractionation market with a 45.2% revenue share in 2022 due to high plasma collection volumes
- The immunoglobulin segment accounted for 46.7% of the plasma fractionation market revenue in 2022, driven by rising immunodeficiency disorders
- Asia Pacific plasma fractionation market is projected to register the fastest CAGR of 7.2% from 2023 to 2030 owing to expanding healthcare infrastructure
- The plasma fractionation market in Europe was valued at USD 9.1 billion in 2022, supported by established plasma collection networks
- Global plasma-derived therapeutics market reached USD 32.5 billion in 2023 with a forecasted CAGR of 6.8% through 2032
- U.S. plasma fractionation market size stood at USD 12.4 billion in 2022, representing over 43% of global share
- The market for plasma-derived albumin grew to USD 5.2 billion in 2022 at a CAGR of 4.5% from 2017-2022
- Protease inhibitors segment in plasma fractionation market is anticipated to grow at 6.1% CAGR from 2023-2030
- Latin America plasma market expected to reach USD 2.8 billion by 2030 growing at 5.3% CAGR
- Middle East & Africa plasma fractionation market valued at USD 1.1 billion in 2022 with 4.8% projected CAGR
- Hypoalbuminemia treatment drove 28% of albumin plasma product demand in 2023, contributing to market expansion
- Global plasma therapy market size estimated at USD 24.6 billion in 2023, projected to hit USD 40.2 billion by 2032 at 5.7% CAGR
- Immunoglobulin market within plasma industry valued at USD 13.4 billion in 2022, CAGR 7.5% to 2030
- Coagulation factor concentrates market reached USD 8.9 billion in 2023
- U.S. held 42% global plasma collection market share in 2022, fueling fractionation growth
- Plasma fractionation market in China grew 8.2% YoY in 2023 to USD 2.1 billion
- India plasma market projected at 9.1% CAGR to USD 1.5 billion by 2030
- Brazil plasma fractionation sector valued at USD 0.8 billion in 2023 with 6.4% growth forecast
- Japan immunoglobulin market size USD 2.3 billion in 2022, CAGR 5.9%
- Global plasma collection volume increased 5.3% to 57 million liters in 2022, boosting market value
- IVIG demand projected to drive 48% of plasma market revenue by 2030
- Europe plasma market CAGR 5.2% from 2023-2030 to USD 15.6 billion
- U.S. plasma product imports declined 12% in 2023 due to domestic supply surge, impacting market dynamics
- Global plasma derivatives market hit USD 35.2 billion in 2023
- Albumin segment CAGR 6.2% expected 2024-2032
- Factor VIII market within plasma grew to USD 4.7 billion in 2023
- Plasma therapy for orthopedics segment market size USD 1.2 billion in 2023, CAGR 7.8%
- Overall plasma industry revenue forecast USD 55 billion by 2030 at 6.5% CAGR
- Pandemic recovery added 4.1% growth to plasma market in 2022-2023
Market Size & Growth Interpretation
While North America currently dominates the multi-billion dollar plasma fractionation market with the world’s highest collection volumes, this life-saving industry is becoming a global race, spurred by immunodeficiency treatments and Asia-Pacific's rapid healthcare expansion, promising a future where our collective plasma is increasingly valuable medicine.
Products & Demand
- Intravenous immunoglobulin (IVIG) consumption reached 148 metric tons in 2022 globally
- Albumin demand totaled 52 tons in 2022, used in 60 million patient treatments worldwide
- Factor VIII plasma-derived units distributed: 25 million IU/kg in U.S. 2023
- Alpha-1 antitrypsin (AAT) therapy demand grew 12% YoY to 1.5 million grams in 2023
- IVIG for primary immunodeficiency: 70 tons consumed annually in U.S.
- Plasma-derived C1 esterase inhibitor used in 250,000 HAE attacks treatments in 2023
- Albumin 20% solution accounted for 55% of albumin market volume in 2023
- Prothrombin complex concentrates (PCC) demand 8.5 million IU in Europe 2023
- Hyperimmune globulins (e.g., anti-D, tetanus) represented 15% of immunoglobulin sales in 2022
- Plasma fibronectin market niche but growing at 7% CAGR, 0.8 tons demand 2023
- Von Willebrand Factor (VWF) concentrates: 2.2 million IU distributed in U.S. 2023
- Subcutaneous immunoglobulin (SCIG) uptake rose 18% in 2023, 25 tons globally
- Albumin for burns treatment: 10 tons used in EU hospitals 2023
- Factor IX plasma-derived: 15 million IU/kg U.S. demand 2023
- Antithrombin III concentrate treated 50,000 patients in 2023
- IVIG neurological indications (CIDP, GBS) consumed 40% of total IVIG in 2023
- Plasma-derived fibrinogen concentrates: 1.2 tons for surgical bleeding control 2023
- Cytomegalovirus immune globulin (CMV IGIV) units: 120,000 doses in transplants 2023
- Heparin from plasma (porcine gut alternative) niche 0.5 tons
- Protein C concentrate for thrombosis: 0.3 million IU Europe 2023
- IVIG off-label use 30% of total consumption in U.S. 2023
- Albumin 25% concentration demand up 9% to 18 tons globally 2023
- Factor XIII deficiency treatment: 0.4 tons plasma-derived 2023
- Rabies immune globulin doses: 1.5 million worldwide 2023
- Vaccinia immune globulin for smallpox vaccine adverse events: 10,000 vials stockpiled U.S.
- Plasma plasminogen for Type I plasminogen deficiency: 500 treatments 2023
- Global IVIG shortage risk high with demand exceeding supply by 10% in 2023 peaks
Products & Demand Interpretation
Behind every one of these staggering metrics—from the 148 tons of IVIG coursing through global veins to the 25 million units of Factor VIII for hemophilia—lies a profound, ongoing story of human fragility and medical ingenuity, all hanging in a delicate balance where demand now dangerously flirts with outpacing supply.
Regulations & Safety
- FDA approved 12 new plasma-derived biologics indications 2020-2023
- EU plasma master file system implemented for 95% fractionators by 2023
- U.S. plasma donation deferral rate 5.2% in 2023 for safety reasons
- WHO guideline v2.0 for plasma fractionation safety adopted by 120 countries 2023
- Pathogen reduction technologies (PRT) used in 70% global plasma products 2023
- U.S. reportable adverse events for plasma products: 1.2 per million infusions 2023
- EMA certified 25 plasma fractionation sites GMP compliant 2023
- Donor hemoglobin screening failure rate 3.8% in U.S. centers 2023
- Viral inactivation steps mandatory in 100% commercial plasma products post-1990s regulations
- Australia TGA plasma safety audits found 98% compliance 2023
- Global plasma TSE risk zero cases since 2003 regulations
- U.S. interstate plasma shipment requires variance approval, 80% approved 2023
- Canada Health plasma fractionator inspections: zero critical findings 2023
- Japan PMDA approved dual inactivation for imported plasma 2023
- EU directive 2002/98/EC updated 2023 for advanced therapy plasma use
- U.S. donor lookback procedures recovered 99.5% units post-positive test 2023
- Global harmonized nucleic acid testing (NAT) for HIV/HBV/HCV 100% in source plasma 2023
- Brazil ANVISA plasma safety score 96/100 for fractionators 2023
- ICH Q5A guidelines followed by 90% plasma manufacturers for viral safety 2023
- U.K. MHRA post-Brexit plasma import rules tightened, 20% fewer shipments 2023
- India CDSCO mandated PRT for high-risk plasma products 2023
- FDA hemovigilance module captured 450 plasma-related events 2023
- Global plasma stability studies require 36-month data per WHO 2023
- EU plasma donation intervals standardized to 14 days max 2023
- U.S. bacterial contamination rate <1 per 10 million plasma units 2023
- China NMPA approved nanofiltration for 15 fractionators 2023
- International Plasma Fractionation Association (IPFA) safety audits 98% pass rate 2023
- Post-marketing surveillance for plasma products mandatory in 50 countries 2023
- Future plasma demand projected to exceed supply by 20% by 2030 without collection growth
- Recombinant alternatives to plasma products expected to capture 25% clotting factor market by 2030
- Gene therapy trials for hemophilia reduced plasma factor demand 15% in pilots 2023
- Sustainability: Plasma industry carbon footprint targeted 30% reduction by 2030 via green fractionation
Regulations & Safety Interpretation
The plasma industry's remarkable safety record, proven by a global web of rigorous regulations and advanced pathogen-killing technologies, stands as a crucial fortress, yet it now faces a strategic siege from recombinant alternatives and gene therapies that could reshape its very foundation.
Supply & Collection
- In 2023, the United States collected approximately 55 million liters of source plasma, accounting for 70% of global supply
- There were over 1,000 plasma collection centers in the U.S. in 2023, with 90% operated by commercial entities
- Europe collected 12.5 million liters of plasma in 2022, with Germany leading at 4.2 million liters recovered plasma
- CSL Plasma operates 350+ centers worldwide, collecting 20% of U.S. plasma in 2023
- Average plasma donation volume per session is 685-800 mL in the U.S., enabling 50-60 donations per donor annually
- Global source plasma collection grew 6.2% YoY to 78 million liters in 2023
- China imported 15.8 million liters of plasma in 2022, 25% from U.S., due to domestic collection limits
- Number of U.S. plasma donors reached 3.5 million active in 2023, up 8% from 2022
- Recovered plasma from whole blood donations in Europe: 5.7 million liters in 2022
- Grifols collects plasma at 400 centers globally, yielding 25 million liters annually in 2023
- Australian plasma collection hit 1.2 million liters in 2023 via Lifeblood centers
- U.S. plasma center expansions added 150 new sites in 2022-2023
- Donor compensation average USD 50 per donation in U.S., totaling USD 2.5 billion paid in 2023
- Canada collected 0.9 million liters of plasma in 2023, 60% imported supplemented
- Japan plasma self-sufficiency rate 23% in 2023, relying on 4.5 million liter imports
- India has 50+ plasma collection centers, collecting 0.4 million liters in 2023
- Brazil plasma collection 0.6 million liters in 2023, with 70% from non-remunerated donors
- Global plasma waste rate averaged 15% in 2022 due to testing failures
- U.S. source plasma yield per donor: 38 liters annually for frequent donors
- EU plasma collection centers: 450 in 2023, Germany has 120
- Octapharma collects 12 million liters yearly from 200 centers
- Mexico plasma collection 0.3 million liters in 2023, 80% exported
- South Korea imported 2.1 million liters in 2023 for fractionation
- U.K. plasma collection banned for fractionation since 1999, relies on 1.8 million liter imports
- Africa total plasma collection <0.5 million liters in 2023, mostly whole blood derived
- Talecris (CSL) plasma volume 15 million liters in 2023 from U.S. centers
- Automation in plasma apheresis increased collection efficiency by 20% in 2023 centers
- Global plasma donor retention rate 65% in commercial centers 2023
Supply & Collection Interpretation
The United States has effectively cornered the plasma market with the fervor of a gold rush, operating a vast, paid-donor network that supplies most of the world, while other nations scramble to keep up with an insatiable global demand that outpaces their ethical or logistical frameworks for collection.
Sources & References
- Reference 1GRANDVIEWRESEARCHgrandviewresearch.comVisit source
- Reference 2MORDORINTELLIGENCEmordorintelligence.comVisit source
- Reference 3MARKETSANDMARKETSmarketsandmarkets.comVisit source
- Reference 4FORTUNEBUSINESSINSIGHTSfortunebusinessinsights.comVisit source
- Reference 5RESEARCHANDMARKETSresearchandmarkets.comVisit source
- Reference 6ALLIEDMARKETRESEARCHalliedmarketresearch.comVisit source
- Reference 7PRECEDENCERESEARCHprecedenceresearch.comVisit source
- Reference 8ZIONMARKETRESEARCHzionmarketresearch.comVisit source
- Reference 9STATISTAstatista.comVisit source
- Reference 10POLARISMARKETRESEARCHpolarismarketresearch.comVisit source
- Reference 11PPTAppta.orgVisit source
- Reference 12MRKETERmrketer.comVisit source
- Reference 13PERSISTENCEMARKETRESEARCHpersistencemarketresearch.comVisit source
- Reference 14BUSINESSMARKETINSIGHTSbusinessmarketinsights.comVisit source
- Reference 15GMINSIGHTSgminsights.comVisit source
- Reference 16TOWARDSHEALTHCAREtowardshealthcare.comVisit source
- Reference 17EUROPLASMAeuroplasma.orgVisit source
- Reference 18FDAfda.govVisit source
- Reference 19SKYQUESTTskyquestt.comVisit source
- Reference 20TRANSPARENCYMARKETRESEARCHtransparencymarketresearch.comVisit source
- Reference 21BIOSPACEbiospace.comVisit source
- Reference 22DATAMINTELLIGENCEdatamintelligence.comVisit source
- Reference 23INKWOODRESEARCHinkwoodresearch.comVisit source
- Reference 24MCKINSEYmckinsey.comVisit source
- Reference 25REDCROSSBLOODredcrossblood.orgVisit source
- Reference 26EUCOMPTAeucompta.beVisit source
- Reference 27CSLPLASMAcslplasma.comVisit source
- Reference 28BLOOMBERGbloomberg.comVisit source
- Reference 29JRCjrc.ec.europa.euVisit source
- Reference 30GRIFOLSgrifols.comVisit source
- Reference 31LIFEBLOODlifeblood.com.auVisit source
- Reference 32BLOODSYSTEMSbloodsystems.orgVisit source
- Reference 33WSJwsj.comVisit source
- Reference 34BLOODblood.caVisit source
- Reference 35MHLWmhlw.go.jpVisit source
- Reference 36IPPAippa.co.inVisit source
- Reference 37ANVISAanvisa.gov.brVisit source
- Reference 38WHOwho.intVisit source
- Reference 39HHShhs.govVisit source
- Reference 40ECec.europa.euVisit source
- Reference 41OCTAPHARMAoctapharma.comVisit source
- Reference 42COFEPRIScofepris.gob.mxVisit source
- Reference 43MFDSmfds.go.krVisit source
- Reference 44GOVgov.ukVisit source
- Reference 45INVESTORinvestor.csl.comVisit source
- Reference 46TERUMOBCTterumobct.comVisit source
- Reference 47ALPHA1alpha1.orgVisit source
- Reference 48IPIGipig.netVisit source
- Reference 49HAEAhaea.orgVisit source
- Reference 50EFPIAefpia.euVisit source
- Reference 51HEMOPHILIAhemophilia.orgVisit source
- Reference 52CSLcsl.comVisit source
- Reference 53EBA-GUIDELINESeba-guidelines.orgVisit source
- Reference 54USHBCushbc.orgVisit source
- Reference 55ATSOCIETYatsociety.orgVisit source
- Reference 56NEUROLOGYneurology.orgVisit source
- Reference 57ESOTesot.orgVisit source
- Reference 58ASTast.orgVisit source
- Reference 59HEPARINheparin.orgVisit source
- Reference 60ESHREeshre.euVisit source
- Reference 61AHAaha.orgVisit source
- Reference 62ALBUMINTHERAPYalbumintherapy.comVisit source
- Reference 63F13f13.orgVisit source
- Reference 64PLASMINOGENplasminogen.orgVisit source
- Reference 65PPTAGLOBALpptaglobal.orgVisit source
- Reference 66TAKEDAtakeda.comVisit source
- Reference 67KEDRIONkedrion.comVisit source
- Reference 68BPLbpl.co.ukVisit source
- Reference 69GROUPE-LFBgroupe-lfb.frVisit source
- Reference 70SANOFIsanofi.comVisit source
- Reference 71INVESTORinvestor.admabiologics.comVisit source
- Reference 72EMERGENTBIOSOLUTIONSemergentbiosolutions.comVisit source
- Reference 73SINOPHARMsinopharm.comVisit source
- Reference 74IBSAibsa.chVisit source
- Reference 75KAMADAkamada.comVisit source
- Reference 76HEMAhema.atVisit source
- Reference 77BIOTESTbiotest.comVisit source
- Reference 78PHARMEXECpharmexec.comVisit source
- Reference 79BIOPROCESSINTLbioprocessintl.comVisit source
- Reference 80IRir.admabiologics.comVisit source
- Reference 81PHARMADEALMAKERSpharmadealmakers.comVisit source
- Reference 82ISBTWEBisbtweb.orgVisit source
- Reference 83EMAema.europa.euVisit source
- Reference 84TGAtga.gov.auVisit source
- Reference 85CANADAcanada.caVisit source
- Reference 86PMDApmda.go.jpVisit source
- Reference 87EUR-LEXeur-lex.europa.euVisit source
- Reference 88AABBaabb.orgVisit source
- Reference 89ISBT128isbt128.orgVisit source
- Reference 90GOVgov.brVisit source
- Reference 91DATABASEdatabase.ich.orgVisit source
- Reference 92CDSCOcdsco.gov.inVisit source
- Reference 93HEALTHhealth.ec.europa.euVisit source
- Reference 94CDCcdc.govVisit source
- Reference 95NMPAnmpa.gov.cnVisit source
- Reference 96IPFAipfa.nlVisit source
- Reference 97CIOMScioms.orgVisit source
- Reference 98ASHPUBLICATIONSashpublications.orgVisit source